Literature DB >> 21936536

Synthesis and Toll-like receptor 4 (TLR4) activity of phosphatidylinositol dimannoside analogues.

Gary D Ainge1, William John Martin, Benjamin J Compton, Colin M Hayman, David S Larsen, Sung-Il Yoon, Ian A Wilson, Jacquie L Harper, Gavin F Painter.   

Abstract

A series of five PIM(2) analogues were synthesized and tested for their ability to activate primary macrophages and modulate LPS signaling. Structural changes included replacement of the fatty acid esters of the phosphatidyl moiety of PIM(2) with the corresponding ether or amide. An AcPIM(2) analogue possessing an ether linkage was also prepared. The synthetic methodology utilized an orthogonally protected chiral myo-inositol starting material that was conveniently prepared from myo-inositol in just two steps. Important steps in the synthetic protocols included the regio- and α-selective glycosylation of inositol O-6 and introduction of the phosphodiester utilizing phosphoramidite chemistry. Replacement of the inositol core with a glycerol moiety gave compounds described as phosphatidylglycerol dimannosides (PGM(2)). Biological testing of these PIM compounds indicated that the agonist activity was TLR4 dependent. An ether linkage increased agonist activity. Removal of the inositol ring enhanced antagonist activity, and the presence of an additional lipid chain enhanced LPS-induced cytokine production in primary macrophages. Furthermore, the interruption of the LPS-induced 2:2 TLR4/MD-2 signaling complex formation by PIM(2) represents a previously unidentified mechanism involved in the bioactivity of PIM molecules.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21936536      PMCID: PMC3280216          DOI: 10.1021/jm2008419

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  39 in total

Review 1.  Chemical approaches for the study of the mycobacterial glycolipids phosphatidylinositol mannosides, lipomannan and lipoarabinomannan.

Authors:  Benjamin Cao; Spencer J Williams
Journal:  Nat Prod Rep       Date:  2010-04-14       Impact factor: 13.423

2.  Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells.

Authors:  Martin Mempel; Catherine Ronet; Felipe Suarez; Martine Gilleron; Germain Puzo; Luc Van Kaer; Agnès Lehuen; Philippe Kourilsky; Gabriel Gachelin
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

3.  Different Toll-like receptor agonists induce distinct macrophage responses.

Authors:  B W Jones; T K Means; K A Heldwein; M A Keen; P J Hill; J T Belisle; M J Fenton
Journal:  J Leukoc Biol       Date:  2001-06       Impact factor: 4.962

4.  Synthesis of a core arabinomannan oligosaccharide of Mycobacterium tuberculosis.

Authors:  Alexandra Hölemann; Bridget L Stocker; Peter H Seeberger
Journal:  J Org Chem       Date:  2006-10-13       Impact factor: 4.354

5.  Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105.

Authors:  Senad Divanovic; Aurelien Trompette; Sowsan F Atabani; Rajat Madan; Douglas T Golenbock; Alberto Visintin; Robert W Finberg; Alexander Tarakhovsky; Stefanie N Vogel; Yasmine Belkaid; Evelyn A Kurt-Jones; Christopher L Karp
Journal:  Nat Immunol       Date:  2005-04-24       Impact factor: 25.606

6.  Mycobacterial phosphatidylinositol mannoside is a natural antigen for CD1d-restricted T cells.

Authors:  Karsten Fischer; Emmanuel Scotet; Marcus Niemeyer; Heidrun Koebernick; Jens Zerrahn; Sophie Maillet; Robert Hurwitz; Mischo Kursar; Marc Bonneville; Stefan H E Kaufmann; Ulrich E Schaible
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-08       Impact factor: 11.205

7.  Acylation state of the phosphatidylinositol hexamannosides from Mycobacterium bovis bacillus Calmette Guerin and mycobacterium tuberculosis H37Rv and its implication in Toll-like receptor response.

Authors:  Martine Gilleron; Valérie F J Quesniaux; Germain Puzo
Journal:  J Biol Chem       Date:  2003-05-29       Impact factor: 5.157

8.  Synthesis of 2-O-hexadecanoyl-1-O-hexadecyl-[alpha-Glc-6SO3 Na-(1--6) -alpha-Glc-(1--6)-alpha-Glc-(1--3)]- sn-glycerol: a proposed structure for the glyceroglucolipids of human gastric secretion and of the mucous barrier of rat-stomach antrum.

Authors:  T Ogawa; T Horisaki
Journal:  Carbohydr Res       Date:  1983-11-11       Impact factor: 2.104

9.  Synthesis of a key Mycobacterium tuberculosis biosynthetic phosphoinositide intermediate.

Authors:  K N Jayaprakash; Jun Lu; Bert Fraser-Reid
Journal:  Bioorg Med Chem Lett       Date:  2004-07-16       Impact factor: 2.823

10.  MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4.

Authors:  R Shimazu; S Akashi; H Ogata; Y Nagai; K Fukudome; K Miyake; M Kimoto
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

View more
  4 in total

1.  Recombinant expression of TLR5 proteins by ligand supplementation and a leucine-rich repeat hybrid technique.

Authors:  Minsun Hong; Sung-Il Yoon; Ian A Wilson
Journal:  Biochem Biophys Res Commun       Date:  2012-09-16       Impact factor: 3.575

2.  Synthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4).

Authors:  Peter Wipf; Benjamin R Eyer; Yukihiro Yamaguchi; Feng Zhang; Matthew D Neal; Chhinder P Sodhi; Misty Good; Maria Branca; Thomas Prindle; Peng Lu; Jeffrey L Brodsky; David J Hackam
Journal:  Tetrahedron Lett       Date:  2015-06-03       Impact factor: 2.415

3.  Total synthesis of tetraacylated phosphatidylinositol hexamannoside and evaluation of its immunomodulatory activity.

Authors:  Pratap S Patil; Ting-Jen Rachel Cheng; Medel Manuel L Zulueta; Shih-Ting Yang; Larry S Lico; Shang-Cheng Hung
Journal:  Nat Commun       Date:  2015-06-03       Impact factor: 14.919

4.  Rational Design of a New Class of Toll-Like Receptor 4 (TLR4) Tryptamine Related Agonists by Means of the Structure- and Ligand-Based Virtual Screening for Vaccine Adjuvant Discovery.

Authors:  Jan Honegr; Rafael Dolezal; David Malinak; Marketa Benkova; Ondrej Soukup; Joyce S F D de Almeida; Tanos C C Franca; Kamil Kuca; Roman Prymula
Journal:  Molecules       Date:  2018-01-04       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.